5+ day, 11+ hour ago   (444+ words) The United States National Institutes of Health has agreed to fund a multimillion-dollar program that will give up to 200 Americans living with motor neurone disease access to an experimental treatment developed by the Melbourne-based biotechnology company Neurizon Therapeutics. The grant,…...

2+ week, 14+ hour ago   (279+ words) Alterity Therapeutics has secured an underwriting agreement that could provide at least $4.2 million in additional funding as the company prepares to begin its planned Phase 3 clinical trial of ATH434 in multiple system atrophy. The Melbourne- and San Francisco-based biotechnology company said…...

2+ week, 6+ day ago   (394+ words) Nanosonics has entered financial year 2027 with continued growth from its trophon disinfection business, while advancing the commercial rollout of its CORIS endoscope reprocessing platform and commencing a new on-market share buyback of up to $40 million. Revenue rose 3 per cent to…...

3+ week, 4+ day ago   (551+ words) Dimerix has received a US$10 million upfront payment from Everest Medicines under its commercial licensing agreement for its lead kidney disease candidate, DMX-200, adding further financial weight to the Melbourne biotechnology company’s push towards a pivotal Phase 3 readout. The payment, worth…...

3+ week, 4+ day ago   (655+ words) Medical Developments International reported higher profitability and stronger cash generation, with accelerating demand for Penthrox in Australia and Europe supporting a more positive outlook for the emergency pain relief specialist. The company reported net profit after tax of $0.6 million for…...